The progress and prospects of live biotherapeutics on cancer immunotherapy
The gut microbiota is considered an indispensable organ and plays an important role in human health. Numbers
of diseases ranging from chronic inflammatory, metabolic diseases to neurological disorders and cancer were associated with the
compositional and functional changes in the gut microbiota. Cancer immunotherapy such as immune checkpoint inhibitor (ICI) is
an emerging treatment with high specificity and efficacious. Recent studies showed that the efficacy of ICIs in patients with
cancer was associated with the gut microbiota. In this review, we summarized studies on cancer immunotherapy?associated gut
microbes, including the function of the gut microbiota in cancer immunotherapy, the potential mechanisms on how it affects the
cancer immunotherapy. For example, metabolites and surface proteins of gut microbes could inhibit tumor growth or induce the
apoptosis of tumor via direct or indirect mechanisms, or modulate the immune system especially in the tumor microenvironment.
The development of bioinformatic tools and statistical approaches along with the application in the analysis of gut microbiota
accelerated the discovery of new gut microbes associated with cancer immunotherapy. Up to now, there are several organizations
and pharmaceutical companies involving in the development of live biotherapeutic products targeting cancer immunotherapy.
Numerous clinical trials have been registered and launched based on the fundamental researches on gut microbiota. In this
review, we also summarized the computational methods for identifying candidate therapeutic bacterium, as well as the
development of live therapeutics on cancer immunotherapy. We also discussed the challenges of current live therapeutics
discoveries on cancer immunotherapy and prospective development trends.
Shenzhen Xbiome Co. Ltd, Shenzhen 518057, Guangdong, China
Abstract：The gut microbiota is considered an indispensable organ and plays an important role in human health. Numbers
of diseases ranging from chronic inflammatory, metabolic diseases to neurological disorders and cancer were associated with the
compositional and functional changes in the gut microbiota. Cancer immunotherapy such as immune checkpoint inhibitor (ICI) is
an emerging treatment with high specificity and efficacious. Recent studies showed that the efficacy of ICIs in patients with
cancer was associated with the gut microbiota. In this review, we summarized studies on cancer immunotherapy⁃associated gut
microbes, including the function of the gut microbiota in cancer immunotherapy, the potential mechanisms on how it affects the
cancer immunotherapy. For example, metabolites and surface proteins of gut microbes could inhibit tumor growth or induce the
apoptosis of tumor via direct or indirect mechanisms, or modulate the immune system especially in the tumor microenvironment.
The development of bioinformatic tools and statistical approaches along with the application in the analysis of gut microbiota
accelerated the discovery of new gut microbes associated with cancer immunotherapy. Up to now, there are several organizations
and pharmaceutical companies involving in the development of live biotherapeutic products targeting cancer immunotherapy.
Numerous clinical trials have been registered and launched based on the fundamental researches on gut microbiota. In this
review, we also summarized the computational methods for identifying candidate therapeutic bacterium, as well as the
development of live therapeutics on cancer immunotherapy. We also discussed the challenges of current live therapeutics
discoveries on cancer immunotherapy and prospective development trends.
张宇龙，许晓敏，阳奕琰，尹意铭，郝淮杰，寇岩，谭验. 活菌药物在肿瘤免疫治疗中的应用进展和未来展望[J]. 肿瘤代谢与营养电子杂志, 2021, 8(2): 198-204.
Zhang Yulong, Xu Xiaomin, Yang Yiyan, Yin Yiming, Hao Huaijie, Kou Yan, Tan Yan. The progress and prospects of live biotherapeutics on cancer immunotherapy. Electron J Metab Nutr Cancer, 2021, 8(2): 198-204.
